Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2x2 Factorial Design Biomarker Tertiary Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. the ASAMET Trial

NCT03047837 is registered in ClinicalTrials.gov with Ente Ospedaliero Ospedali Galliera as lead sponsor.

NCT NCT03047837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03047837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2x2 Factorial Design Biomarker Tertiary Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. the ASAMET Trial
Lead sponsor
Ente Ospedaliero Ospedali Galliera
Phase
Phase 2
Overall status
Terminated
Start date
March 15, 2017
Completion date
March 31, 2024
Enrollment
160 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tertiary prevention in colon cancer